Tandem Diabetes Care, Inc. provided sales guidance for the fourth quarter and full year ended December 31, 2017 and year ending December 31, 2018. For the fourth quarter, the company’s GAAP sales increased to approximately $39 million to $40 million from $28.9 million. Non-GAAP sales increased to approximately $39 million to $40 million from $24.8 million. Pump shipments increased to approximately 7,000 pumps from 4,418 pumps. For the year ended December 31, 2017, the company’s GAAP sales increased to approximately $106 million to $107 million from $84.2 million. Non-GAAP sales increased to approximately $101 million to $102 million from $88.5 million. Pump shipments increased to approximately 17,100 pumps from 16,938 pumps. For the year ending December 31, 2018, the company’s GAAP sales are estimated to be in the range of $132 million to $140 million, an estimated year-over-year increase of approximately 23% to 32% to its preliminary 2017 GAAP sales. When comparing to its preliminary 2017 sales on a non-GAAP basis, the estimated year-over-year increase is approximately 29% to 39%.